Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era

Front Immunol. 2022 Aug 8:13:1002615. doi: 10.3389/fimmu.2022.1002615. eCollection 2022.

Authors

Alberto Mussetti^{1

2}, Enrico Derenzini^{3

4}, Sarkozy Clementine⁵, Anna Sureda^{1

2

6}

Affiliations

¹ Department of Hematology, Catalan Institute of Oncology, Barcelona, Spain.
² Institut d'Investigacio Biomedica de Bellvitge (IDIBELL), Barcelona, Spain.
³ Department of Hematology, European Institute of Oncology (IEO), Milan, Italy.
⁴ University of Milan, Milan, Italy.
⁵ Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy Cancer Campus, Villejuif, France.
⁶ University of Barcelona, Barcelona, Spain.

No abstract available

Keywords: CART; Lymphoma; bispecific antibodies; cell therapy; monoclonal antibodies.

Publication types

Editorial

MeSH terms

Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Rituximab

Substances

Rituximab